The Evolving HER2+ Metastatic Breast Cancer Treatment Landscape

home / around-the-practice / the-evolving-her2-metastatic-breast-cancer-treatment-landscape

A panel of experts review data from recent conferences and discuss core challenges in the treatment of patients with HER2+ metastatic breast cancer.

EP. 1: Treatment Landscape for HER2+ Metastatic Breast Cancer

Andrew D. Seidman, MD;Aditya Bardia, MD, MPH;Mark D. Pegram, MD;Ruta Rao, MD

November 16th 2021

Panelists provide an overview of the treatment landscape for patients with HER2-positive metastatic breast cancer.

EP. 2: Treating Recurrent HER2+ Metastatic Breast Cancer Given Recent Clinical Trials

Andrew D. Seidman, MD;Aditya Bardia, MD, MPH;Mark D. Pegram, MD;Ruta Rao, MD

November 16th 2021

A panel of experts reviews clinical trial data in recurrent HER2-positive metastatic breast cancer and discusses impacts on treatment selection.

EP. 3: Considerations for HER2+ mBC Management: Biomarkers and Bone Disease

Andrew D. Seidman, MD;Aditya Bardia, MD, MPH;Mark D. Pegram, MD;Ruta Rao, MD

November 23rd 2021

Fielding questions from a live audience, experts discuss the lack of biomarkers in HER2+ metastatic breast cancer and how one might address progression of bone disease.

EP. 4: Patient Case #1: Frontline Therapy for HER2+ mBC

Andrew D. Seidman, MD;Aditya Bardia, MD, MPH;Mark D. Pegram, MD;Ruta Rao, MD

November 23rd 2021

Using a patient case to center their discussion, the panel reviews frontline treatment options for HER2+ metastatic breast cancer and the rationale behind selection.

EP. 5: Patient Case #1: Second-Line Therapy for HER2+ mBC

Andrew D. Seidman, MD;Aditya Bardia, MD, MPH;Mark D. Pegram, MD;Ruta Rao, MD

November 30th 2021

Moving to optimal treatment approaches in second-line therapy, experts close out a patient case of HER2+ metastatic breast cancer.

EP. 6: Patient Case #2: Third-Line Options for HER2+ mBC With Lung Disease

Andrew D. Seidman, MD;Aditya Bardia, MD, MPH;Mark D. Pegram, MD;Ruta Rao, MD

November 30th 2021

In another patient case, panelists break down third-line therapy options for someone with HER2+ metastatic breast cancer and lung disease.

EP. 7: Audience Questions on Selecting Optimal Therapy for mBC

Andrew D. Seidman, MD;Aditya Bardia, MD, MPH;Mark D. Pegram, MD;Ruta Rao, MD

December 8th 2021

Panelists field questions from a live audience regarding the optimal selection of therapy for patients with metastatic breast cancer.

EP. 8: Patient Case #3: Sequencing Therapy and Monitoring Results

Andrew D. Seidman, MD;Aditya Bardia, MD, MPH;Mark D. Pegram, MD;Ruta Rao, MD

December 8th 2021

Centering their conversation on a patient case, experts discuss the sequencing and monitoring of therapy in patients with HER2+ metastatic breast cancer.

EP. 9: Reflections on Future Treatment Strategies for HER2+ mBC

Andrew D. Seidman, MD;Aditya Bardia, MD, MPH;Mark D. Pegram, MD;Ruta Rao, MD

December 8th 2021

Experts close out their discussion on the management of HER2+ metastatic breast cancer by highlighting their hopes for future treatment strategies.